Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).

Joly, P; Horwath, B; Patsatsi, Α; Uzun, S; Bech, R; Beissert, S; Bergman, R; Bernard, P; Borradori, L.; Caproni, M; Caux, F; Cianchini, G; Daneshpazhooh, M; De, D; Dmochowski, M; Drenovska, K; Ehrchen, J; Feliciani, C; Goebeler, M; Groves, R; ... (2020). Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology : JEADV, 34(9), pp. 1900-1913. Wiley 10.1111/jdv.16752

Text jdv.16752.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (821kB)

BACKGROUND

Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States.

OBJECTIVES

The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus.

RESULTS

The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.

Interest & Impact

Downloads

2 since deposited on 10 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item